Global COVID-19 Antigen Testing Kits Market Size By Type (PCR, Qpcr), By Application (Hospitals, Scientific Research), By Region, And Segment Forecasts, 2023 to 2032

The Global COVID-19 Antigen Testing Kits Market was valued at USD 6.1 billion in 2023 and is expected to surpass USD 8.4 billion by 2031, growing at a CAGR of 4.0% during the forecast period from 2023 to 2031. The market has experienced a robust expansion driven by the need for rapid and accessible COVID-19 diagnostics in both clinical and non-clinical settings. These kits play a pivotal role in early detection, mass testing, and controlling the spread of the virus, particularly in emerging economies and remote regions where RT-PCR testing facilities are limited.

Drivers:

1. Continued Global Surveillance and Pandemic Preparedness:

As COVID-19 variants continue to emerge, global health systems remain committed to surveillance and rapid detection. Antigen tests offer quick results and are critical for monitoring infection spikes, especially in high-traffic and vulnerable areas such as airports, schools, and eldercare facilities.

2. Government and Institutional Support:

Substantial public sector procurement and initiatives from global health organizations, including the WHO and CDC, have sustained demand. These include stockpiling and distribution for potential future outbreaks or variant-driven surges.

3. Increased Point-of-Care Adoption:

The demand for point-of-care diagnostics has escalated, with antigen kits being favored due to their cost-effectiveness, speed, and ease of use. Their role in home testing, travel screening, and workplace safety has further fueled market penetration.

Restraints:

1. Reduced Sensitivity Compared to Molecular Tests:

Although convenient, antigen tests are generally less sensitive than RT-PCR, leading to higher false-negative rates in asymptomatic individuals. This diagnostic gap can challenge the credibility of results in some scenarios.

2. Regulatory Variability and Compliance:

The differing regulatory standards across countries can hinder global distribution and market entry for new players. Moreover, evolving compliance requirements for emergency use authorization (EUA) can delay product launches.

Opportunity:

1. Integration with Digital Health Platforms:

Companies are leveraging digital transformation by integrating antigen testing kits with mobile apps for result tracking, telehealth consultations, and automated reporting. This convergence is creating new business models and improving data-driven pandemic management.

2. Emerging Market Penetration:

Many low- and middle-income countries continue to rely on affordable, easy-to-use antigen testing kits. Expanding distribution networks and public-private partnerships offer lucrative growth avenues in these regions.

Market by System Type Insights:

Lateral Flow Assay (LFA) kits dominate the market due to their ease of use, affordability, and suitability for mass screening programs. These kits are extensively used in home-based testing and point-of-care settings. However, the microfluidic immunoassay kits segment is gaining traction for offering better accuracy and automation capabilities in clinical environments.

Market by End-use Insights:

In 2023, the Diagnostic Laboratories segment accounted for the largest revenue share. These facilities rely heavily on rapid antigen tests for preliminary screening before confirmatory PCR testing. Meanwhile, the Home Care segment is experiencing significant growth, driven by increased consumer access to over-the-counter (OTC) test kits, spurred by government approvals and retail availability.

Market by Regional Insights:

North America led the market in 2023, supported by widespread testing protocols, government funding, and the presence of key players. However, Asia-Pacific is projected to register the fastest growth during the forecast period, fueled by population density, increased testing awareness, and government initiatives across India, China, and Southeast Asian countries.

Competitive Scenario:

Key players operating in the global COVID-19 antigen testing kits market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Quidel Corporation, BD (Becton, Dickinson and Company), Siemens Healthineers, LumiraDx, Access Bio, and SD Biosensor Inc. These companies are continually innovating through next-generation kits, digital platform integrations, and global distribution partnerships. Notable developments include:

2023: Abbott Laboratories launched an AI-powered antigen test reader compatible with smartphones for home use.

2024: SD Biosensor partnered with several Asian governments to supply cost-effective antigen kits for rural testing campaigns.

2025: Quidel introduced a multiplex antigen testing platform capable of detecting COVID-19, Influenza A/B, and RSV simultaneously.

Scope of Work – Global COVID-19 Antigen Testing Kits Market

Key Market Developments:

Abbott expanded its antigen kit manufacturing capacity to meet sustained global demand.

Roche launched a new digital platform for antigen test data aggregation and health monitoring.

LumiraDx received CE-marking for its enhanced sensitivity antigen test targeted for asymptomatic screening.

FAQs:

1) What is the current market size of the COVID-19 Antigen Testing Kits Market?

The market was valued at USD 6.1 billion in 2023.

2) What is the major growth driver of the COVID-19 Antigen Testing Kits Market?

The primary growth drivers include the continued need for global pandemic surveillance and the rising adoption of point-of-care diagnostics.

3) Which is the largest region during the forecast period in the COVID-19 Antigen Testing Kits Market?

North America held the largest share in 2023, while Asia-Pacific is expected to grow the fastest during the forecast period.

4) Which segment accounted for the largest market share in the COVID-19 Antigen Testing Kits Market?

The Lateral Flow Assay segment held the largest share due to its widespread application in rapid and home testing.

5) Who are the key market players in the COVID-19 Antigen Testing Kits Market?

Key players include Abbott Laboratories, Roche, Quidel Corporation, BD, Siemens Healthineers, LumiraDx, Access Bio, and SD Biosensor Inc.